Belgian biotech company Agomab Therapeutics raises a €94.9M Series C to tackle fibrosis 

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Here are details of Agomab‘s latest funding round :

🚀 Launch

2017

🏭 Industry

Biotechnology

🧠Management

Tim Knotnerus (CEO), Philippe Wiesel (Chief Medical Officer), Andrea Sáez (Chief Development Officer), Tolga Hassan (CFO), Paul van der Horst (Chief Business Officer)

💸 Funding & Investors

INVESTMENT (October 2023)€94.9 million (Series C)
INVESTORS (October 2023)led by Fidelity Management & Research Company, with participation from new investors EQT Life Sciences (EQT), Canaan, Dawn Biopharma, a platform controlled by KKR, and existing investors.

🎯 Funding purpose

Support its Phase 2a clinical trial, STENOVA, which will evaluate the effectiveness of the lead candidate AGMB-129. The drug is a gut-restricted small molecule inhibitor of ALK5 and will be tested on patients with Fibrostenosing Crohn’s Disease (FSCD).

🌐 Country HQ

Belgium (Ghent)

Leave a Reply

Your email address will not be published.